ArticleJournal of immunology (Baltimore, Md. : 1950)2014

Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms.

Ding Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.